Fenwick & West represented Mavupharma, Inc., a drug discovery and development company focused on non-nucleotide modulators of the STING pathway to treat cancer and infectious diseases, in its $20 million Series A funding. Frazier Healthcare Partners led the round with participation from Alpine BioVentures.

Mavu will use the funds to advance its drug candidates into the clinic. More information about Mavu’s $20 million Series A financing can be obtained from the company announcement.

The Fenwick transaction team was led by corporate lawyers Matt Rossiter, Katherine Duncan, Liz Federowicz and Daniel Renz.

Login

Don’t have an account yet?

Register